These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25645199)

  • 1. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
    Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
    Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Cowan DA; Bassett EE; Stow M; Sönksen PH; Holt RI
    Drug Test Anal; 2012 Jun; 4(6):455-9. PubMed ID: 22511534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
    Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score.
    Erotokritou-Mulligan I; Eryl Bassett E; Cowan DA; Bartlett C; Milward P; Sartorio A; Sönksen PH; Holt RI
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):520-6. PubMed ID: 19650783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
    Kniess A; Ziegler E; Thieme D; Müller RK
    J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methodology for age-adjustment of the GH-2000 score detecting growth hormone misuse.
    Böhning D; Böhning W; Guha N; Cowan DA; Sönksen PH; Holt RI
    BMC Med Res Methodol; 2016 Oct; 16(1):147. PubMed ID: 27793179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
    Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
    J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker detection of rhGH doping: an excretion study.
    Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
    Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
    Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
    J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
    Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
    Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport.
    Abellan R; Ventura R; Pichini S; Pascual JA; Pacifici R; Di Carlo S; Bacosi A; Segura J; Zuccaro P
    Clin Chem Lab Med; 2005; 43(1):75-85. PubMed ID: 15653447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
    Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
    Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes.
    Erotokritou-Mulligan I; Bassett EE; Bartlett C; Cowan D; McHugh C; Seah R; Curtis B; Wells V; Harrison K; Sönksen PH; Holt RI;
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2760-3. PubMed ID: 18413420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving one step closer to catching the GH cheats: The GH-2004 experience.
    Holt RI; Bassett EE; Erotokritou-Mulligan I; McHugh C; Cowan D; Bartlett C; Sönksen PH;
    Growth Horm IGF Res; 2009 Aug; 19(4):346-51. PubMed ID: 19467613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ethnicity on IGF-I and procollagen III peptide (P-III-P) in elite athletes and its effect on the ability to detect GH abuse.
    Erotokritou-Mulligan I; Bassett EE; Cowan DA; Bartlett C; McHugh C; Sönksen PH; Holt RI;
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):161-8. PubMed ID: 18616716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.
    Cowan DA; Moncrieffe DA
    Drug Test Anal; 2022 May; 14(5):808-819. PubMed ID: 34418311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
    Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.